Related Experiment Video
Updated: May 4, 2026
Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice
Published on: April 15, 2014
Matrine regulates glutamate-related excitotoxic factors in experimental autoimmune encephalomyelitis
Quan-Cheng Kan1, Su Zhang1, Yu-Ming Xu1
1Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China.
Abstract:
It is increasingly accepted that glutamate excitotoxicity contributes to the death of nerve cells in multiple sclerosis (MS). Matrine (MAT) is a quinolizidine alkaloid that has long been used in the treatment of hepatitis B without obvious side effects. Previous reports have shown that MAT suppresses central nervous system inflammation and demyelination in experimental autoimmune encephalomyelitis (EAE), an animal model of MS; however whether MAT effectively inhibits excitotoxic molecules, such as glutamate-related factors, is still unclear. In this study, we provide data showing that MAT attenuated EAE disease severity, accompanied by downregulated glutamate and upregulated GABA levels, as well as enhanced expression of two dependent glutamate transporters (GLT-1 and GLAST). In addition, MAT treatment significantly reduced the level of the NMDA- and AMPA-glutamate receptor in EAE rats. Taken together, our data indicate that MAT treatment regulates glutamate-related molecules, and suggests that the neuroprotective role of MAT is a novel mechanism underlying its therapeutic effect in EAE.
Insights
Matrine (MAT) reduces multiple sclerosis (MS) severity by regulating glutamate and GABA levels. This neuroprotective effect involves modulating glutamate transporters and receptors, offering a novel therapeutic mechanism for MS.
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Glutamate excitotoxicity is implicated in nerve cell death in multiple sclerosis (MS).
- Matrine (MAT), a traditional herbal medicine, shows anti-inflammatory and anti-demyelination effects in experimental autoimmune encephalomyelitis (EAE), an MS animal model.
- The precise impact of MAT on glutamate-related excitotoxicity in MS remains unclear.
Purpose of the Study:
- To investigate the effect of MAT on glutamate excitotoxicity in an EAE model of MS.
- To determine if MAT modulates glutamate and GABA levels, glutamate transporters, and glutamate receptors in EAE rats.
Main Methods:
- Administration of MAT to EAE rats.
- Measurement of glutamate and GABA levels.
- Assessment of glutamate transporter (GLT-1, GLAST) expression.
- Quantification of NMDA and AMPA glutamate receptor levels.
Main Results:
- MAT treatment attenuated EAE disease severity.
- MAT downregulated glutamate and upregulated GABA levels in EAE rats.
- MAT enhanced the expression of glutamate transporters GLT-1 and GLAST.
- MAT significantly reduced NMDA and AMPA glutamate receptor levels in EAE rats.
Conclusions:
- MAT treatment effectively regulates glutamate-related molecules in the EAE model.
- MAT exhibits neuroprotective effects by modulating glutamate excitotoxicity.
- These findings suggest a novel therapeutic mechanism for MAT in MS treatment.
More Related Videos
10:46Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
Published on: May 3, 2017
08:47Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
Published on: May 8, 2016
